REG - Hemogenyx Pharma Plc - Notice of AGM

Hemogenyx PharmaceuticalsAnnouncement

05/06/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260605:nRSE9025Ga&default-theme=true

RNS Number : 9025G  Hemogenyx Pharmaceuticals PLC  05 June 2026

 

5 June 2026

 

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

 

Posting of Annual Report & Notice of Annual General Meeting

 

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group,
confirms that the Annual Report and Accounts for the year ended 31 December
2025, the Notice of the Annual General Meeting ("AGM") and a Form of Proxy
will be posted to shareholders today and will shortly be available on the
Company's website
at https://hemogenyx.com/investors/annual-half-year-reports/
(https://hemogenyx.com/investors/annual-half-year-reports/) .

 

The AGM is to be held on 30 June 2026 at 2.00 pm BST at One Heddon Street,
London, W1B 4BD.

 

Enquiries:

 

 Hemogenyx Pharmaceuticals plc                                   https://hemogenyx.com (https://hemogenyx.com/)
 Dr Vladislav Sandler, Chief Executive Officer & Co-Founder      headquarters@hemogenyx.com (mailto:headquarters@hemogenyx.com)
 Peter Redmond, Director                                         peter.redmond@hemogenyx.com (mailto:peter.redmond@hemogenyx.com)
 SP Angel Corporate Finance LLP                                  Tel: +44 (0)20 3470 0470
 Matthew Johnson, Vadim Alexandre, Adam Cowl
 AlbR Capital Limited                                            Tel: +44 (0)20 7469 0930
 Lucy Williams, Duncan Vasey, Charles Goodfellow

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO)
headquartered in London, with its US operating subsidiaries, Hemogenyx
Pharmaceuticals LLC and Immugenyx LLC, located in New York City.

The Company is a clinical-stage biopharmaceutical group developing new
medicines and treatments to treat blood and autoimmune diseases. Hemogenyx
Pharmaceuticals is developing several distinct and complementary product
candidates, as well as platform technologies that it uses as engines for novel
product development.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOASSFFIDEMSEIM



            Copyright 2019 Regulatory News Service, all rights reserved